Rigel Pharmaceuticals, Inc.

Knight Therapeutics announced COFEPRIS approval for TAVALISSE® (fostamatinib) to treat chronic ITP in Mexico, offering a new therapeutic option for adult patients with insufficient response to prior treatments. The approval marks a significant step in expanding ITP treatment options and reinforces Knight's commitment to improving patient outcomes in Latin America, with plans to launch TAVALISSE® in Mexico by mid-2026.

Rigel Pharmaceuticals announces FDA Fast Track designation for R289, a dual IRAK1/4 inhibitor, in treating transfusion-dependent lower-risk myelodysplastic syndrome (LR-MDS).

Personalized therapy for NSCLC has advanced with biomarker testing, notably NGS, identifying driver mutations for targeted treatments improving OS. MET alterations in NSCLC, including exon 14 skipping mutations, are targeted by MET tyrosine kinase inhibitors like crizotinib, capmatinib, and tepotinib. RET fusions in NSCLC are addressed by selective RET inhibitors selpercatinib and pralsetinib. KRAS G12C mutations are managed with selective KRAS G12C inhibitors sotorasib and adagrasib, showing significant efficacy in clinical trials.